In most melanomas, the mutation rarely occurs in BRAF and NRAS simultaneously, but when there is a mutation in any of these proteins, MEK activation occurs (MAPK pathway), and there is also the activation of the PI3K pathway, consequently, there will be an excess of expression of the inflammatory factors, growth factors, and the suppression of apoptotic factors [3,4,27]. The gene discussed is NRAS; the disease is melanoma.